Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4

Kaori Miyazaki, Yoichiro Abe, Hiroko Iwanari, Yota Suzuki, Takahiro Kikuchi, Takashi Ito, Jungo Kato, Osamu Kusano-Arai, Toshiyuki Takahashi, Shuhei Nishiyama, Hiroko Ikeshima-Kataoka, Shoji Tsuji, Takeshi Arimitsu, Yasuhiro Kato, Toshiko Sakihama, Yoshiaki Toyama, Kazuo Fujihara, Takao Hamakubo, Masato Yasui

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalJournal of Neuroimmunology
Volume260
Issue number1-2
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Immunoglobulin G
Monoclonal Antibodies
Aquaporin 4
Neuromyelitis Optica
Baculoviridae
Demyelinating Diseases
Autoantibodies
Therapeutics

Keywords

  • Aquaporin-4
  • Monoclonal antibody
  • NMO-IgG
  • Nueromyelitis optica

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. / Miyazaki, Kaori; Abe, Yoichiro; Iwanari, Hiroko; Suzuki, Yota; Kikuchi, Takahiro; Ito, Takashi; Kato, Jungo; Kusano-Arai, Osamu; Takahashi, Toshiyuki; Nishiyama, Shuhei; Ikeshima-Kataoka, Hiroko; Tsuji, Shoji; Arimitsu, Takeshi; Kato, Yasuhiro; Sakihama, Toshiko; Toyama, Yoshiaki; Fujihara, Kazuo; Hamakubo, Takao; Yasui, Masato.

In: Journal of Neuroimmunology, Vol. 260, No. 1-2, 2013, p. 107-116.

Research output: Contribution to journalArticle

Miyazaki, K, Abe, Y, Iwanari, H, Suzuki, Y, Kikuchi, T, Ito, T, Kato, J, Kusano-Arai, O, Takahashi, T, Nishiyama, S, Ikeshima-Kataoka, H, Tsuji, S, Arimitsu, T, Kato, Y, Sakihama, T, Toyama, Y, Fujihara, K, Hamakubo, T & Yasui, M 2013, 'Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4', Journal of Neuroimmunology, vol. 260, no. 1-2, pp. 107-116. https://doi.org/10.1016/j.jneuroim.2013.03.003
Miyazaki, Kaori ; Abe, Yoichiro ; Iwanari, Hiroko ; Suzuki, Yota ; Kikuchi, Takahiro ; Ito, Takashi ; Kato, Jungo ; Kusano-Arai, Osamu ; Takahashi, Toshiyuki ; Nishiyama, Shuhei ; Ikeshima-Kataoka, Hiroko ; Tsuji, Shoji ; Arimitsu, Takeshi ; Kato, Yasuhiro ; Sakihama, Toshiko ; Toyama, Yoshiaki ; Fujihara, Kazuo ; Hamakubo, Takao ; Yasui, Masato. / Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. In: Journal of Neuroimmunology. 2013 ; Vol. 260, No. 1-2. pp. 107-116.
@article{de00b469f45d476fa8606c28cd90e1de,
title = "Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4",
abstract = "Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.",
keywords = "Aquaporin-4, Monoclonal antibody, NMO-IgG, Nueromyelitis optica",
author = "Kaori Miyazaki and Yoichiro Abe and Hiroko Iwanari and Yota Suzuki and Takahiro Kikuchi and Takashi Ito and Jungo Kato and Osamu Kusano-Arai and Toshiyuki Takahashi and Shuhei Nishiyama and Hiroko Ikeshima-Kataoka and Shoji Tsuji and Takeshi Arimitsu and Yasuhiro Kato and Toshiko Sakihama and Yoshiaki Toyama and Kazuo Fujihara and Takao Hamakubo and Masato Yasui",
year = "2013",
doi = "10.1016/j.jneuroim.2013.03.003",
language = "English",
volume = "260",
pages = "107--116",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4

AU - Miyazaki, Kaori

AU - Abe, Yoichiro

AU - Iwanari, Hiroko

AU - Suzuki, Yota

AU - Kikuchi, Takahiro

AU - Ito, Takashi

AU - Kato, Jungo

AU - Kusano-Arai, Osamu

AU - Takahashi, Toshiyuki

AU - Nishiyama, Shuhei

AU - Ikeshima-Kataoka, Hiroko

AU - Tsuji, Shoji

AU - Arimitsu, Takeshi

AU - Kato, Yasuhiro

AU - Sakihama, Toshiko

AU - Toyama, Yoshiaki

AU - Fujihara, Kazuo

AU - Hamakubo, Takao

AU - Yasui, Masato

PY - 2013

Y1 - 2013

N2 - Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

AB - Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

KW - Aquaporin-4

KW - Monoclonal antibody

KW - NMO-IgG

KW - Nueromyelitis optica

UR - http://www.scopus.com/inward/record.url?scp=84878644469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878644469&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2013.03.003

DO - 10.1016/j.jneuroim.2013.03.003

M3 - Article

C2 - 23746426

AN - SCOPUS:84878644469

VL - 260

SP - 107

EP - 116

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -